PsoriasisDX, the first commercially available genetic test for psoriatic arthritis, can help detect the condition before symptoms develop, allowing for less joint damage through early treatment. This is important because medications for psoriatic arthritis can prevent joint destruction but not reverse damage once it occurs. Using the PsoriasisDX Genetic Test kit, a cheek swab sample is sent to the laboratory for analysis. The gene variant MICA-A9 is found in approximately 60% of those who develop PsA; if the variant is not present, the patient has an approximately 70% chance of not getting the condition. The kit is $399 and available through qualified physicians.

PsoriasisDX

www.psoriasisdx.com